enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received an average rating of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is $34.40.

Separately, Oppenheimer initiated coverage on shares of enGene in a report on Wednesday. They issued an “outperform” rating and a $30.00 price objective for the company.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently made changes to their positions in the stock. Altitude Crest Partners Inc. acquired a new stake in enGene during the 1st quarter valued at approximately $2,039,000. SR One Capital Management LP acquired a new stake in shares of enGene during the second quarter worth $4,715,000. Vivo Capital LLC bought a new position in enGene during the fourth quarter worth $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the fourth quarter valued at $10,441,000. Finally, Logos Global Management LP lifted its stake in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the period. 64.16% of the stock is currently owned by institutional investors.

enGene Stock Performance

enGene stock opened at $6.53 on Wednesday. The stock has a fifty day moving average of $8.03 and a 200-day moving average of $12.12. The stock has a market capitalization of $288.40 million, a P/E ratio of -4.01 and a beta of -0.63. enGene has a 52 week low of $4.94 and a 52 week high of $43.00.

enGene (NASDAQ:ENGN) last issued its earnings results on Friday, June 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.14). On average, research analysts forecast that enGene will post -1.33 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.